Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.

Antimicrobial and antimotility agents are not recommended for the treatment of Shiga toxin-producing Escherichia coli O157 infection. In our study, many persons with Shiga toxin-producing E. coli O157 infection took antimicrobial (62%) and antimotility agents (32%); 43 (29%) of 146 reported commencing antimicrobial treatment after laboratory confirmation. Efforts are needed to promote practice guidelines.

[1]  Y. Yahata.  Risk factors for sporadic shiga toxin-producing escherichia coli O157 infections in Japan , 2013 .

[2]  P. Griffin,et al.  Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Tobin-D'Angelo,et al.  Preliminary FoodNet Data on the incidence of infection with pathogens transmitted commonly through food--10 States, 2008. , 2009, MMWR. Morbidity and mortality weekly report.

[4]  W. Schaffner,et al.  Stool cultures and antimicrobial prescriptions related to infectious diarrhea. , 2008, The Journal of infectious diseases.

[5]  Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 states, 2007. , 2008, MMWR. Morbidity and mortality weekly report.

[6]  E. Scallan.  Activities, achievements, and lessons learned during the first 10 years of the Foodborne Diseases Active Surveillance Network: 1996-2005. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Jones,et al.  Sporadic Campylobacter Infection in Infants: A Population-Based Surveillance Case-Control Study , 2007, The Pediatric infectious disease journal.

[8]  P. Mead,et al.  Risk factors for sporadic Shiga toxin-producing Escherichia coli O157 infections in FoodNet sites, 1999–2000 , 2006, Epidemiology and Infection.

[9]  T. Jones,et al.  A Case-Control Study of the Epidemiology of Sporadic Salmonella Infection in Infants , 2006, Pediatrics.

[10]  A. Cronquist,et al.  Antimicrobial use and outcomes in patients with multidrug-resistant and pansusceptible Salmonella Newport infections, 2002-2003. , 2005, Microbial drug resistance.

[11]  L. Slutsker,et al.  Farm visits and undercooked hamburgers as major risk factors for sporadic Escherichia coli O157:H7 infection: data from a case-control study in 5 FoodNet sites. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Guerrant,et al.  Clinical practice. Acute infectious diarrhea. , 2004, The New England journal of medicine.

[13]  R. Guerrant,et al.  Acute Infectious Diarrhea , 2004 .

[14]  P. Mead,et al.  Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. , 2002, Journal of the American Medical Association (JAMA).

[15]  R. Gangnon,et al.  Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. , 2002, JAMA.

[16]  P. Murdoch,et al.  The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Wallace,et al.  The role of antibiotics in the treatment of infectious diarrhea. , 2001, Gastroenterology clinics of North America.

[18]  L B Reller,et al.  Practice guidelines for the management of infectious diarrhea. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Craig S. Wong,et al.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.

[20]  J. Wells,et al.  A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. , 1998, The Journal of infectious diseases.

[21]  B. Bell,et al.  Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. , 1997, Pediatrics.

[22]  H. Dupont,et al.  Adverse effect of lomotil therapy in shigellosis. , 1973, JAMA.